PharmaKB Updates

Novel FDA Drug Approvals - 3rd Quarter of 2023 - PharmaKB Report

Written by Jason Bret Harris, PhD | Oct 1, 2023 9:21:00 PM

 

The Pharmaceutical KnowledgeBase (PharmaKB.com) provides research and financial intelligence about companies and their approved drugs as well as drug candidates in clinical trials. In this quarterly PharmaKB report, we provide an update about novel drugs approved by the US FDA in of this year.  By referencing new drugs as “novel” the FDA is confirming that the medicine being approved contains ingredients and/or a mechanism of action that the FDA hasn’t previously approved. 

2023 | July | August | September

 

 

July 2023 – Novel FDA Drug Approvals

Nirsevimab-alip

Quizartinib

Lotilaner


 

 

August 2023 – Novel FDA Drug Approvals

Zuranolone

Avacincaptad pegol

Talquetamab-tgvs

Elranatamab-bcmm

Palovarotene

Pozelimab-bbfg

 

 

September 2023 – Novel FDA Drug Approvals

Motixafortide

Momelotinib

Gepirone

Cipaglucosidase alfa-atga

Nedosiran

FDA News Release: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215842s000lbl.pdf